The Lancet: June 22, 2007

Matthew During, author of a phase I study of gene therapy in the treatment of Parkinson's disease dicusses the study, designed to assess safety and tolerability, shows encouraging early results for the treatment of Parkinson's disease and other neurodegenerative disorders. Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://you...